(Q56929067)

1

0 references

Bishnu De

3

0 references

Ju Joh

4

0 references

Julie Boyer

5

0 references

Ronald G. Crystal

6

0 references

Stefan Worgall

Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth

7

0 references

language of work or name

English

0 references

publication date

August 2008

0 references

published in

Virology

0 references

volume

378

0 references

issue

1

0 references

page(s)

79-85

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Immunization strategies for the prevention of pneumovirus infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Passive antibody therapy for infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Stable antibody expression at therapeutic levels using the 2A peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Clades of Adeno-associated viruses are widely disseminated in human tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Respiratory syncytial virus and parainfluenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Human recombinant neutralizing antibodies against hantaan virus G2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Baculovirus expression of a human G2-specific, neutralizing IgG monoclonal antibody to Puumala virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

High In Vivo Production of a Model Monoclonal Antibody on Adenoviral Gene Transfer

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

inferred from DOI database lookup

7 January 2021

based on heuristic

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

The future of respiratory syncytial virus vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Immunopathology of RSV infection: prospects for developing vaccines without this complication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.016